Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Claudia Ligorio"'
Autor:
Michele Mishto, Elena Bellavista, Claudia Ligorio, Kathrin Textoris-Taube, Aurelia Santoro, Mara Giordano, Sandra D'Alfonso, Florinda Listì, Benedetta Nacmias, Elena Cellini, Maurizio Leone, Luigi M E Grimaldi, Chiara Fenoglio, Federica Esposito, Filippo Martinelli-Boneschi, Daniela Galimberti, Elio Scarpini, Ulrike Seifert, Maria Pia Amato, Calogero Caruso, Maria P Foschini, Peter M Kloetzel, Claudio Franceschi
Publikováno v:
PLoS ONE, Vol 5, Iss 2, p e9287 (2010)
BackgroundAlbeit several studies pointed out the pivotal role that CD4+T cells have in Multiple Sclerosis, the CD8+ T cells involvement in the pathology is still in its early phases of investigation. Proteasome degradation is the key step in the prod
Externí odkaz:
https://doaj.org/article/4cb4cbf2336142ff9d2394e21649e691
Publikováno v:
Acta Bio Medica : Atenei Parmensis
A single case of ultrasonographic-guided local injection of methotrexate for managing scar pregnancy is reported. The outcome was successful and had no side effects. The case was reported to increase the evidence supporting this type of management.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f5db061ef7545b51d9b598c0589377cf
http://hdl.handle.net/11392/2457695
http://hdl.handle.net/11392/2457695
Autor:
Annarita Destro, Silvia Bozzarelli, Luca Di Tommaso, Lorenza Rimassa, Armando Santoro, Laura Giordano, Tiziana Pressiani, Carlo Carnaghi, Massimo Roncalli, Claudia Ligorio, Maria Chiara Tronconi, Nicola Personeni
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 139:1179-1187
Preclinical studies show that sorafenib, a multitarget kinase inhibitor, displays anti-proliferative, anti-angiogenic, and pro-apoptotic properties in hepatocellular carcinoma (HCC). However, the determinants of sorafenib sensitivity in vivo remain l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57d4b754f9ae29f4cc027d5eaa4f437e
https://doi.org/10.1007/s00432-013-1429-x
https://doi.org/10.1007/s00432-013-1429-x
Autor:
Clinical Lung Cancer Genome Project, Network Genomic Medicine, Biospecimens, data source sites: Alex Soltermann, Holger Moch, Odd Terje Brustugun, Steinar Solberg, Marius Lund Iversen, Åslaug Helland, Thomas Muley, Hans Hoffmann, Philipp A. Schnabel, Yuan Chen, Harry Groen, Wim Timens, Hannie Sietsma, Joachim H. Clement, Walter Weder, Jörg Sänger, Erich Stoelben, Corinna Ludwig, Walburga Engel Riedel, Egbert Smit, Daniëlle A. M. Heideman, Peter J. F. Snijders, Lucia Nogova, Martin L. Sos, Christian Mattonet, Karin Töpelt, Matthias Scheffler, Eray Goekkurt, Rainer Kappes, Stefan Krüger, Kato Kambartel, Dirk Behringer, Wolfgang Schulte, Wolfgang Galetke, Winfried Randerath, Matthias Heldwein, Andreas Schlesinger, Monika Serke, Khosro Hekmat, Konrad F. Frank, Roland Schnell, Marcel Reiser, Ali Nuri Hünerlitürkoglu, Stephan Schmitz, Lisa Meffert, Yon Dschun Ko, Markus Litt Lampe, Ulrich Gerigk, Rainer Fricke, Benjamin Besse, Christian Brambilla, Sylvie Lantuejoul, Philippe Lorimier, Denis Moro Sibilot, Federico Cappuzzo, Claudia Ligorio, John K. Field, Russell Hyde, Pierre Validire, Philippe Girard, Lucia A. Muscarella, Vito M. Fazio, Michael Hallek, Jean Charles Soria, Scott L. Carter, Gad Getz, D. Neil Hayes, Matthew D. Wilkerson, Viktor Achter, Ulrich Lang, DAMIANI, STEFANIA
We characterized genome alterations in 1255 clinically annotated lung tumors of all histological subgroups to identify genetically defined and clinically relevant subtypes. More than 55% of all cases had at least one oncogenic genome alteration poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::410e1c81df998d7d7d2c499895fea568
http://hdl.handle.net/11585/396000
http://hdl.handle.net/11585/396000
Autor:
Stefania Vetrano, Francesca Tognoli, Tommaso Stefanelli, Silvio Danese, Alberto Malesci, Alessandro Repici, Paolo Omodei, Claudia Ligorio, Carmen Correale, Elisabetta Dejana
Publikováno v:
Gastroenterology. 134:A-656
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa789d5928c928195da1abef6f17c67b
https://doi.org/10.1016/s0016-5085(08)63064-4
https://doi.org/10.1016/s0016-5085(08)63064-4
Autor:
Federico, Cappuzzo, Claudia, Ligorio, Claudio, Ligorio, Luca, Toschi, Elisa, Rossi, Rocco, Trisolini, Daniela, Paioli, Elisabetta, Magrini, Giovanna, Finocchiaro, Stefania, Bartolini, Alessandra, Cancellieri, Fred R, Hirsch, Lucio, Crino, Marileila, Varella-Garcia
Publikováno v:
Journal of Thoracic Oncology. (5):423-429
Background A critical point in designing clinical trials comparing chemotherapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC) is the expected benefit with standard che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98e87313192557b0290994ac9452ae3e